Loading…
CVM
Cel Sci Corp
NYSE American· Healthcare· Biotechnology· CUSIP 150837706
$1.56-2.50%Price as of Aug 29, 18:35 UTC · updated once a day, after the close
Key metrics
- Market cap
- $27.44M
- P/E
- —
- Forward P/E
- —
- P/B
- 2.5x
- Dividend yield
- —
- Payout
- —
- EPS
- -$1.65
- ROE
- -252.53%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 0.56
- 52-week high
- $12.68
- 52-week low
- $0.89
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -99.5% over 5Y.
today you would have $5.07▼ -99.5%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $5.26 | $12.00 | $81.60 | $70.50 | |
| P/B | 2.9x | 2.6x | 2.0x | 9.8x | 3.2x |
| EPS | -$6.27 | -$15.31 | -$21.90 | -$26.10 | |
| ROE | -184.23% | -159.25% | -209.22% | -243.62% | -114.11% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| PLRZPolyrizon Ltd. | $13.15 | — | 1.0x | — | -25.38% | $27.39M |
| BYSIBeyondSpring Inc. | $0.67 | — | — | — | — | $27.36M |
| ARAYAccuray Inc | $0.23 | — | 0.6x | — | -80.08% | $26.93M |
| FEMYFemasys Inc | $3.20 | — |
About the company
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
- Vienna, United States
Company description provided by Yahoo Finance.